- IND for VG-3927 now open; Phase 1 clinical trial in healthy volunteers allowed to proceed with partial clinical hold related to maximum exposure limit – - Phase 1 dosing expected to commence in ...

Good day, and thank you for standing by. Welcome to the Structure Therapeutics top line results from the aleniglipron Phase II Access Program. [Operator Instructions] Please be advised that today's ...

BOSTON, March 4, 2026 /PRNewswire/ -- HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, allosteric small molecules that target natural regulatory ...

Structural complexity in modern small molecules is reshaping what drug development partners must deliver from discovery through commercial supply.Targeted protein degraders, covalent agents, and a new ...

The MarketWatch News Department was not involved in the creation of this content. -- The preclinical, small molecule program offers a potential first-in-class, oral, precision immunometabolic approach ...

BOSTON, June 4, 2026 /PRNewswire/ -- HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, allosteric small molecules that target natural regulatory ...

Arrakis Therapeutics Inc. has presented data on its RNA-targeted small-molecule (rSM) drug program for the treatment of myotonic dystrophy type 1 (DM1). The company’s proprietary RNA‐specific chemical ...

CRANBURY, N.J., Nov. 4, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the ...

“As the first company to advance a small molecule TREM2 agonist into clinical development, we are excited to present data from this important program at AAIC,” said David Gray, Ph.D., Chief Science ...

FARMINGDALE, N.Y., June 15, 2023 (GLOBE NEWSWIRE) -- DepYmed, Inc. (“DepYmed” or the “Company”) is a preclinical stage pharmaceutical company focused on developing transformative treatments for rare ...

HotSpot Therapeutics, Inc. is a biotechnology company that is pioneering a new class of allosteric drugs that target certain naturally occurring pockets on proteins called "natural hotspots." These ...